CENTOGENElogo.jpg
CENTOGENE Announces Virtual Investor Event
June 07, 2021 06:30 ET | CENTOGENE GmbH
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, June 07, 2021 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose,...
CENTOGENElogo.jpg
CENTOGENE Initiates EFRONT Study to Identify Patients With Genetic Forms of Frontotemporal Dementia
June 02, 2021 06:31 ET | CENTOGENE GmbH
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, June 02, 2021 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose,...
CENTOGENElogo.jpg
CENTOGENE Launches NEW CentoXome® - An Enhanced Whole Exome Sequencing Solution
June 01, 2021 06:30 ET | CENTOGENE GmbH
World leader and trusted partner in rare diseases releases enhanced Whole Exome Sequencing (WES) solution to improve diagnosis in complex and unsolved patient casesNEW CentoXome® provides...
CENTOGENElogo.jpg
CENTOGENE Announces the Nomination of Rene Just as Chief Financial Officer
May 26, 2021 06:30 ET | CENTOGENE GmbH
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, May 26, 2021 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose,...
CENTOGENElogo.jpg
CENTOGENE Appoints Michael Motz as Chief Commercial Officer, Pharmaceuticals
May 18, 2021 06:30 ET | CENTOGENE GmbH
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, May 18, 2021 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world...
CENTOGENElogo.jpg
CENTOGENE Extends Global Parkinson’s Disease Study
May 10, 2021 06:30 ET | CENTOGENE GmbH
Providing patients with genetic testing designed to accelerate the diagnosis and personalized treatment of Parkinson’s disease (PD) The Rostock International Parkinson's Disease (ROPAD) Study aims to...
CENTOGENElogo.jpg
New CentoMD® 6.0 Update Brings Deeper Insights Into Rare Diseases
May 06, 2021 06:30 ET | CENTOGENE GmbH
Database has grown to more than 465,000 analyzed patients, with more than 225,000 being linked to HPO termsRelease includes increase of almost 19 million to over 31 million unique variants New...
CENTOGENElogo.jpg
CENTOGENE Discovers Six New Rare Diseases by Leveraging the Strength of Its Bio/Databank
May 05, 2021 06:30 ET | CENTOGENE GmbH
More than half of patients with genetic diseases remain undiagnosed, even after performing Exome and Genome SequencingBy performing deep genetic analyses and Bio/Databank mining, CENTOGENE discovers...
CENTOGENElogo.jpg
CENTOGENE Reports Record Fourth Quarter and Full Year 2020 Financial Results
April 15, 2021 06:30 ET | CENTOGENE GmbH
Revenues more than doubled in FY 2020 compared to FY 2019 to a record €128.4 million, with Q4 2020 revenues nearly quadrupling year-over-year to a record €70.3 millionAchieved highest annual adjusted...
CENTOGENElogo.jpg
CENTOGENE Extends Partnership With Takeda
April 14, 2021 06:30 ET | CENTOGENE GmbH
CAMBRIDGE, Mass., ROSTOCK, Germany and BERLIN, April 14, 2021 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world...